Released Mar 17, 2020, after the close
10-K filed Mar 19, 2020, 79 days after period end · 0001493152-20-004343
Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.17M$5.17M derived−12.7% vs Q4 2018+12.8% vs Q3 2019
Net Income-$1.29M-$1.29M derivedN/M vs Q4 2018N/M vs Q3 2019
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$1,227,000N/M
Operating Cash Flowderived$983,000+17.4%
Free Cash Flowderived$966,000+101.3%
Margins · derived
Operating margin-23.7%−26.7 pt vs Q4 2018
Net margin-25.0%−25.9 pt vs Q4 2018
What the release said
The release
Same quarter
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.17M | $5.92M | $5.30M | $5.98M |
| Net Income | -$1.29M | $52.00K | -$639.00K | -$459.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR